tiprankstipranks
Trending News
More News >
Janux Therapeutics Inc (JANX)
NASDAQ:JANX
US Market
Advertisement

Janux Therapeutics Inc (JANX) Stock Statistics & Valuation Metrics

Compare
437 Followers

Total Valuation

Janux Therapeutics Inc has a market cap or net worth of $1.37B. The enterprise value is $456.12M.
Market Cap$1.37B
Enterprise Value$456.12M

Share Statistics

Janux Therapeutics Inc has 60,093,933 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding60,093,933
Owned by Insiders48.35%
Owned by Institutions0.10%

Financial Efficiency

Janux Therapeutics Inc’s return on equity (ROE) is -0.07 and return on invested capital (ROIC) is -9.45%.
Return on Equity (ROE)-0.07
Return on Assets (ROA)-0.06
Return on Invested Capital (ROIC)-9.45%
Return on Capital Employed (ROCE)-0.09
Revenue Per Employee116.35K
Profits Per Employee-758.18K
Employee Count91
Asset Turnover<0.01
Inventory Turnover0.00

Valuation Ratios

The current PE Ratio of Janux Therapeutics Inc is ―. Janux Therapeutics Inc’s PEG ratio is ―.
PE Ratio
PS Ratio0.00
PB Ratio0.00
Price to Fair Value2.81
Price to FCF0.00
Price to Operating Cash Flow-34.32
PEG Ratio

Income Statement

In the last 12 months, Janux Therapeutics Inc had revenue of 10.59M and earned -68.99M in profits. Earnings per share was -1.28.
Revenue10.59M
Gross Profit8.53M
Operating Income-98.85M
Pretax Income-68.99M
Net Income-68.99M
EBITDA-98.85M
Earnings Per Share (EPS)-1.28

Cash Flow

In the last 12 months, operating cash flow was -876.00K and capital expenditures 0.00, giving a free cash flow of -876.00K billion.
Operating Cash Flow-876.00K
Free Cash Flow-876.00K
Free Cash Flow per Share-0.01

Dividends & Yields

Janux Therapeutics Inc pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share
Dividend Yield
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta1.93
52-Week Price Change-37.62%
50-Day Moving Average24.71
200-Day Moving Average36.61
Relative Strength Index (RSI)39.45
Average Volume (3m)852.01K

Important Dates

Janux Therapeutics Inc upcoming earnings date is Nov 11, 2025, After Close (Confirmed).
Last Earnings DateAug 7, 2025
Next Earnings DateNov 11, 2025
Ex-Dividend Date

Financial Position

Janux Therapeutics Inc as a current ratio of 59.21, with Debt / Equity ratio of 2.23%
Current Ratio59.21
Quick Ratio59.21
Debt to Market Cap<0.01
Net Debt to EBITDA4.12
Interest Coverage Ratio0.00

Taxes

In the past 12 months, Janux Therapeutics Inc has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00

Enterprise Valuation

Janux Therapeutics Inc EV to EBITDA ratio is -24.99, with an EV/FCF ratio of -55.92.
EV to Sales233.31
EV to EBITDA-24.99
EV to Free Cash Flow-55.92
EV to Operating Cash Flow-56.38

Balance Sheet

Janux Therapeutics Inc has $1.01B in cash and marketable securities with $22.61M in debt, giving a net cash position of -$991.53M billion.
Cash & Marketable Securities$1.01B
Total Debt$22.61M
Net Cash-$991.53M
Net Cash Per Share-$16.50
Tangible Book Value Per Share$19.03

Margins

Gross margin is 94.58%, with operating margin of -933.58%, and net profit margin of -651.62%.
Gross Margin94.58%
Operating Margin-933.58%
Pretax Margin-651.62%
Net Profit Margin-651.62%
EBITDA Margin-933.58%
EBIT Margin-933.58%

Analyst Forecast

The average price target for Janux Therapeutics Inc is $75.91, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$75.91
Price Target Upside232.50% Upside
Analyst ConsensusStrong Buy
Analyst Count14
Revenue Growth Forecast28.12%
EPS Growth Forecast-11.01%

Scores

Smart Score8
AI Score45
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis